In our study, we found that high expression of SH3TC2-DT and SH3TC2 were both associated with poor OS, FLT3 mutation, high WBC count, and intermediate cytogenetic and molecular–genetic risk in AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.